Corrigendum to “Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies” (Schizophrenia Research (2016) 174(1–3) (82–92) (S092099641630161X) (10.1016/j.schres.2016.04.012));Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies

Schizophrenia Research

Volumn 174, Issue 1-3, 2016, Pages 82-92

  Correll, Christoph U ^a,b   Skuban, Aleksandar ^c   Hobart, Mary ^c   Ouyang, John ^c   Weiller, Emmanuelle ^d   Weiss, Catherine ^c   Kane, John M ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d H LUNDBECK A S   (Denmark)

Author keywords

Acute; Brexpiprazole; Efficacy; Meta analysis; Placebo; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; PLACEBO; PROLACTIN; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ANXIETY; ARTICLE; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CAUCASIAN; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECT SIZE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; THIOPHENES;

EID: 84964734763     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2017.02.030     Document Type: Erratum

References (34)

1. Agid, O., Siu, C.O., Potkin, S.G., Kapur, S., Watsky, E., Vanderburg, D., Zipursky, R.B., Remington, G., 2013. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am. J. Psychiatry 170 (11) 1335-1344.
2. Alphs L., Benedetti F., Fleischhacker W.W., Kane J.M. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?. Int. J. Neuropsychopharmacol. 2012, 15(7):1003-1014.
3. Carbon M., Correll C.U. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin. Neurosci. 2014, 16:505-524.
4. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS. Drugs. 2013, 27(11):879-911.
5. Cochran W.G. Some methods for strengthening the common χ2 tests. Biometrics 1954, 10(4):417-451.
6. Correll C.U. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010, 25(Suppl. 2):S12-S21.
7. Correll C.U., De Hert M. Antipsychotics for acute schizophrenia: making choices. Lancet 2013, 382(9896):919-920.
8. Correll C.U., Canas F., Larmo I., Levy P., Montes J.M., Fagiolini A., Papageorgiou G., Rossi A., Sturlason R., Zink M. Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry 2011, 26(1 Suppl 1):3-16.
9. Correll C.U., Skuban A., Ouyang J., Hobart M., Pfister S., McQuade R.D., Nyilas M., Carson W.H., Sanchez R., Eriksson H. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2015, 172(9):870-880.
10. Cutler A.J., Marcus R.N., Hardy S.A., O'Donnell A., Carson W.H., McQuade R.D. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS. Spectr. 2006, 11(9):691-702.
11. Davis C.S., Chung Y. Randomization model methods for evaluating treatment efficacy in multicenter clinical trials. Biometrics 1995, 51(3):1163-1174.
12. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011, 8(2):114-126.
13. Ebdrup B.H., Rasmussen H., Arnt J., Glenthoj B. Serotonin 2a receptor antagonists for treatment of schizophrenia. Expert. Opin. Investig. Drugs. 2011, 20(9):1211-1223.
14. Fleischhacker W.W. Aripiprazole. Expert. Opin. Pharmacother. 2005, 6(12):2091-2101.
15. Guy W. Ecdeu assessment manual for psychopharmacology. Hamilton anxiety scale 1976, 193-198. (revised), National Institute of Mental Health, US Department of Health, Education, and Welfare publication (ADM) 76-338, Rockville, MD. M. Hamilton (Ed.).
16. Hochberg Y., Tamhane A. Multiple Comparison Procedures 1987, Wiley, New York, NY.
17. Huhn M., Tardy M., Spineli L.M., Kissling W., Forstl H., Pitschel-Walz G., Leucht C., Samara M., Dold M., Davis J.M., Leucht S. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 2014, 71(6):706-715.
18. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2002, 63(9):763-771.
19. Kane J.M., Skuban A., Ouyang J., Hobart M., Pfister S., McQuade R.D., Nyilas M., Carson W.H., Sanchez R., Eriksson H. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr. Res. 2015, 164(1-3):127-135.
20. Kane J.M., Skuban A., Hobart M., Ouyang J., Weiller E., Weiss C., Correll C.U. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr. Res. 2016, 174(1-3):93-98. (in this issue).
21. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (panss) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
22. 2a receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 2014, 17(5):823-832.
23. Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J. Clin. Psychiatry 2014, 75(Suppl. 1):8-14.
24. Leucht S., Cipriani A., Spineli L., Mavridis D., Örey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lässig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet. 2013, 382(9896):951-962.
25. Leucht S., Heres S., Davis J.M. Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. Am. J. Psychiatry 2013, 170(11):1232-1234.
26. Maeda K., Sugino H., Akazawa H., Amada N., Shimada J., Futamura T., Yamashita H., Ito N., McQuade R.D., Mork A., Pehrson A.L., Hentzer M., Nielsen V., Bundgaard C., Arnt J., Stensbol T.B., Kikuchi T. Brexpiprazole i: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350(3):589-604.
27. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58(12):538-546.
28. McEvoy J.P., Daniel D.G., Carson W.H., McQuade R.D., Marcus R.N. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J. Psychiatr. Res. 2007, 41(11):895-905.
29. Montoya A., Valladares A., Lizan L., San L., Escobar R., Paz S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual. Life Outcomes 2011, 9(18). 10.1186/1477-7525-9-18.
30. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the dsm-iv social and occupational functioning assessment scale (sofas) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101(4):323-329.
31. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60(7):681-690.
32. Rabinowitz J., Berardo C.G., Bugarski-Kirola D., Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a catie analysis. Schizophr. Res. 2013, 150(2-3):339-342.
33. Samara M.T., Leucht C., Leeflang M.M., Anghelescu I.G., Chung Y.C., Crespo-Facorro B., Elkis H., Hatta K., Giegling I., Kane J.M., Kayo M., Lambert M., Lin C.H., Moller H.J., Pelayo-Teran J.M., Riedel M., Rujescu D., Schimmelmann B.G., Serretti A., Correll C.U., Leucht S. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am. J. Psychiatry 2015, 172(7):617-629.
34. Thase M.E., Fava M., Hobart M., Skuban A., Zhang P., McQuade R.D., Carson W.H., Sanchez R., Forbes R.A. Efficacy of adjunctive opc-34712 across multiple outcome measures in major depressive disorder: a phase ii, randomized, placebo-controlled study. Neuropsychopharmacology 2011, 36:S302-S304.